Chandra Bhagat Pharma Peer Comparison

Chandra Bhagat Pharma Ltd. is significantly underperforming its peers across key financial metrics, showing no revenue growth, earnings, or profitability. The company appears to be financially stressed with a debt-equity ratio of zero, but this is coupled with an absence of returns and growth, making it a concern in the current competitive landscape.

• • Chandra Bhagat Pharma has no revenue or earnings growth, making it a laggard in comparison to peers.
• • The company has a zero debt-equity ratio, indicating no debt but also raises concerns about growth prospects.
• • Compared to peers, Chandra Bhagat Pharma's valuation metrics are unattractive, with high PE ratios and no profitability.

• • Cipla Ltd.: Strong revenue growth (YoY: 13.28%) and impressive profitability metrics including high ROE (16.63%) and low PE (23.73).
• • Dr. Reddy's Laboratories Ltd.: Solid overall performance with good profitability (ROE: 21.76%) and attractive valuation (PE: 15.50).
• • Mankind Pharma Ltd.: Impressive revenue growth (YoY: 18.12%) and high profitability metrics, with a solid ROE (23.15%).